论文部分内容阅读
目的主要目的是研究ERCC1、Ki67在子宫内膜癌中的表达,探讨检测ERCC1、Ki67在指导临床治疗的应用价值。方法应用免疫组织化学Envison法检测33例子宫内膜癌中ERCC1与Ki67的表达,并分析二者之间以及与年龄、肿瘤类型的相关性。结果 ERCC1在子宫内膜癌中的表达率为66.67%,Ki67的表达率为57.58%,但子宫内膜癌中的ERCC1表达与Ki67的表达无显著相关性(r s=-0.087,P=0.631)。结论子宫内膜癌的发生发展均可有ERCC1、Ki67的异常表达,二者在子宫内膜癌中表达不呈相关性,但结合二者的表达,可筛选合适的患者接受辅助化疗,有助于个体化治疗的进行。
The main purpose of this study was to investigate the expression of ERCC1 and Ki67 in endometrial carcinoma and explore the value of detecting ERCC1 and Ki67 in guiding the clinical treatment. Methods The expression of ERCC1 and Ki67 in 33 cases of endometrial carcinoma was detected by Envison immunohistochemistry. The correlation between them and with age and tumor type was analyzed. Results The expression of ERCC1 was 66.67% in endometrial carcinoma and 57.58% in Ki67, but there was no significant correlation between the expression of ERCC1 and the expression of Ki67 in endometrial carcinoma (rs = -0.087, P = 0.631) . Conclusions The abnormal expression of ERCC1 and Ki67 may both occur in the development and progression of endometrial carcinoma. The expression of ERCC1 and Ki67 is not correlated with the expression of endometrial carcinoma. However, in combination with the expression of both, suitable patients may be screened for adjuvant chemotherapy, which is helpful In the individualized treatment.